Glasgow biopharmaceutical company EnteroBiotix Limited (‘EnteroBiotix’), as part of their development of best-in-class therapies for gut health, today announced that data from its Phase 2a TrIuMPH trial of EBX-102-02 in 122 adults with IBS-C has been selected for a late-breaking oral presentation at Digestive Disease Week® (DDW) 2025, to be held 3–6 May in San Diego, USA.
EnteroBiotix is a clinical-stage biotechnology company developing microbiome-based therapeutics for irritable bowel syndrome (IBS) and other gastrointestinal and hepatic indications. Using its proprietary platform technology, EnteroBiotix creates next-generation therapies with differentiated characteristics designed to restore and enhance gut microbiome function. The company has established independent control over the supply chain for its drug formulations, with MHRA licensed manufacturing capabilities, and a donor programme called Number2®.
EBX-102-02 is a next-generation, full-spectrum microbiome therapeutic composed of a high-diversity consortium of gut-derived microbes.
Late-Breaker Presentation Details
Presentation Title: A randomised, double-blind, placebo-controlled, phase II trial assessing the safety and efficacy of EBX-102-02, an oral full-spectrum intestinal microbiota product, in patients with irritable bowel syndrome with constipation; the TrIuMPH trial
Presenter: Professor Anthony Hobson
Abstract Number: 987b
Embargoed Until: 06 May 2025, 12:01 am PDT
Session Title: DDW Clinical Science Late-Breaking Abstract Plenary
Session date and Time: 06 May 2025, 08:15-08:30 am PDT
Location: Room 6A (SDCC)
